Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

2.

Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.

PMID:
29194939
3.

High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.

Boerekamps A, Newsum AM, Smit C, Arends JE, Richter C, Reiss P, Rijnders BJA, Brinkman K, van der Valk M; NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational Cohort .

Clin Infect Dis. 2018 Apr 17;66(9):1352-1359. doi: 10.1093/cid/cix1004.

PMID:
29186365
4.

Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells.

Jolink H, de Boer R, Hombrink P, Jonkers RE, van Dissel JT, Falkenburg JH, Heemskerk MH.

J Infect. 2017 Jan;74(1):81-88. doi: 10.1016/j.jinf.2016.10.010. Epub 2016 Nov 9.

PMID:
27838522
5.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study.

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355. Epub 2016 Feb 4.

PMID:
26842457
6.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
7.

Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, Reiss P; ATHENA National Observational HIV Cohort.

BMJ Open. 2016 Jan 4;6(1):e009688. doi: 10.1136/bmjopen-2015-009688.

8.

Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic Analysis.

Bezemer D, Cori A, Ratmann O, van Sighem A, Hermanides HS, Dutilh BE, Gras L, Rodrigues Faria N, van den Hengel R, Duits AJ, Reiss P, de Wolf F, Fraser C; ATHENA observational cohort.

PLoS Med. 2015 Nov 3;12(11):e1001898; discussion e1001898. doi: 10.1371/journal.pmed.1001898. eCollection 2015 Nov.

9.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

10.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

11.

T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens.

Jolink H, de Boer R, Willems LN, van Dissel JT, Falkenburg JH, Heemskerk MH.

Allergy. 2015 Oct;70(10):1336-9. doi: 10.1111/all.12688. Epub 2015 Aug 6.

PMID:
26179335
12.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

13.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
14.

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.

Zhang S, van Sighem A, Kesselring A, Gras L, Prins JM, Hassink E, Kauffmann R, Richter C, de Wolf F, Reiss P; ATHENA national observational HIV cohort study.

HIV Med. 2015 May;16(5):265-72. doi: 10.1111/hiv.12202. Epub 2015 Jan 21.

15.

Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.

Schoffelen AF, Smit C, van Lelyveld SF, Vogt L, Bauer MP, Reiss P, Hoepelman AI, Barth RE; ATHENA National Observational HIV Cohort.

J Infect Dis. 2015 Jul 15;212(2):264-74. doi: 10.1093/infdis/jiv026. Epub 2015 Jan 18.

PMID:
25601941
16.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

17.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.

Gras L, de Wolf F, Smit C, Prins M, van der Meer JT, Vanhommerig JW, Zwinderman AH, Schinkel J, Geskus RB; ATHENA national observational cohort and the MOSAIC study.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

PMID:
25559595
18.

Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.

Rokx C, Fibriani A, van de Vijver DA, Verbon A, Schutten M, Gras L, Rijnders BJ; AIDS Therapy Evaluation in the Netherlands National Observational Cohort.

Clin Infect Dis. 2015 Jan 1;60(1):143-53. doi: 10.1093/cid/ciu763. Epub 2014 Oct 1.

PMID:
25273080
19.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
20.

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group.

HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

Supplemental Content

Loading ...
Support Center